Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

According to recently unveiled statistics by Future Market Insights, the global animal artificial insemination market is set ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.